<DOC>
	<DOCNO>NCT02161978</DOCNO>
	<brief_summary>project pilot prospective , longitudinal , before-after , open label multicentric study .</brief_summary>
	<brief_title>Vascular Dysfunction Antiangiogenic Therapy</brief_title>
	<detailed_description>Antiangiogenic drug tyrosine kinase inhibitor ( TKI ) represent new therapeutic issue treatment several neoplasic tumor ( colon , kidney , breast , lung , skin ) hemopathy . Antiangiogenic drug act neutralization activity ( e.g . bevacizumab ) inhibition post-receptor tyrosine kinase pathway ( e.g . sunatinib , sorafenib ) , lead reduction inhibition tumoral tissular neovascularization . Due ubiquitous role systemic administration antiangiogenic drug , almost responsible several side effect , many involve cardiovascular system ( e.g . arterial hypertension , cardiomyopathy , proteinuria , bleeding , ... ) lead reduction dos withdrawal treatment . To date , mechanism impact cardiovascular effect well understood involve structural ( i.e . capillary rarefaction ) functional vascular dysfunction ( i.e . vasomotor dysfunction , stiffen ) .</detailed_description>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Angiogenesis Inhibitors</mesh_term>
	<criteria>Men woman &gt; 18 year old treat solid tumor ( kidney , pancreas , breast , lung , skin ) line antiangiogneic therapy hemopathy Antiangiogneic therapy : bevacizumab , anti ( e.g . sunitinib , sorafenib ) , proteinate kinase inhibitor ( e.g.temsirolimus ) everolimus new allow therapy expect antiangiogenic property tyrosine kinase inhibitor . Expected life span &gt; 6 month Clinical state allow investigation A blood glucose lipid test within last 3 month Informed consent obtain Patients present clinical state allow performance vascular investigation ( agitation , cutaneous wound , major asthenia , acute dyspnoea , cadiac arhythmia ) Pregnant woman Patients &gt; 18 yr old protect french law Patients without national health insurance Patients include another biomedical study ( criterion relative study )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>antiangiogenic</keyword>
	<keyword>cancer</keyword>
	<keyword>vascular</keyword>
	<keyword>biomarker</keyword>
	<keyword>tyrosine kinase inhibitor</keyword>
</DOC>